O

Olema Oncology

Clinical-stage biopharma targeting ER-positive breast cancer

Senior Director - Patient Safety Sciences

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-time

About the Job

Requirements

  • MD, PhD, PharmD, or MD equivalent from an accredited institution.
  • Strong knowledge of applicable ICH, FDA, and EU regulations and guidelines governing patient safety and pharmacovigilance activities.
  • Comprehensive understanding of the pharmaceutical industry, including emerging trends and developments in drug safety and pharmacovigilance.
  • Experience with registrational clinical development programs and filings is required.
  • A minimum of 15 years of relevant drug-safety experience in the biopharmaceutical industry and specifically in oncology clinical trials.
  • A minimum of 6 years of progressive people leadership experience, including managing, developing, and mentoring high-performing teams.
  • Experience in oncology is required.
  • A track record of strong individual performance and demonstrated success in building, leading, and developing high-performing teams.
  • Demonstrated ability to coach and develop employees, establish clear expectations, manage performance, and foster collaboration, accountability, and continuous learning.
  • Demonstrated experience selecting, managing, and overseeing safety and pharmacovigilance vendors, including setting performance expectations and ensuring quality, compliance, and accountability.
  • Experience providing strategic safety input into clinical study activities and documentation, regulatory submissions, Development Safety Update Reports, Integrated Summaries of Safety, responses to regulatory agency inquiries, pharmacovigilance processes and projects, aggregate safety reports, and risk management plans.
  • Demonstrated expertise in conducting signal detection and benefit-risk evaluation throughout the product lifecycle.
  • Experience providing strategic safety input related to product development.
  • A track record of supporting and leading pharmacovigilance audits and regulatory inspections.
  • Proven capability to lead through organizational growth and change, assume increasing responsibilities as the function evolves, and support effective integration of activities across teams and functions.
  • Experience helping shape departmental goals and objectives, drive process and operational efficiencies, and advance innovative practices within Patient Safety and across the organization.
  • Demonstrated experience establishing and implementing best practices that strengthen quality, compliance, operational effectiveness, and continuous improvement within Patient Safety.
  • Proven ability to work independently, establish priorities, exercise sound judgment, and deliver results with minimal guidance.
  • Ability to set direction, evaluate priorities, adapt to change, resolve conflict, and build effective partnerships.
  • Verbal and written communication skills to communicate complex safety information clearly and effectively to diverse audiences.
  • Ability to collaborate and lead effectively in a dynamic, science-driven, cross-functional environment.
  • Commitment to scientific rigor, quality, compliance, and operational excellence.
  • Ability to learn quickly, identify core challenges, and adjust direction as priorities evolve in a fast-paced organization.
  • Professional ethics, integrity, and judgment.

Responsibilities

  • Lead strategic planning and execution of patient safety activities, collaborate with key departments, recommend pharmacovigilance and risk-management strategies, and lead signal detection, assessment, and evaluation activities.
  • Lead development and authoring of safety-related sections of clinical and regulatory documents, including benefit-risk assessments, protocols, Investigator’s Brochures, informed consent forms, briefing books, core safety information, and other internal and external documents.
  • Provide clinical and medical review of serious adverse events, suspected unexpected serious adverse reactions, and analyses of similar events; review source records and case narratives for accuracy; evaluate MedDRA coding; identify medically relevant queries; determine expectedness based on reference safety information; prepare sponsor assessments; and guide Drug Safety colleagues in determining reportability.
  • Provide safety expertise and leadership in Data Monitoring Committee meetings, including preparation, review, and interpretation of relevant safety data.
  • Lead Safety Sciences activities related to quality systems, audits, inspection readiness, and regulatory inspections, maintaining consistent compliance and preparedness.
  • Develop and deliver safety-related training for employees, cross-functional partners, and clinical site personnel to promote accountability for patient safety and regulatory compliance.
  • Build, lead, and develop a high-performing Safety Sciences team; coach and mentor direct reports and junior team members; establish goals and expectations; delegate responsibilities; monitor performance and workload; and foster accountability, professional growth, collaboration, and continuous improvement.
  • Assess organizational capabilities and resource requirements for the Safety Sciences function, identifying and addressing talent, capacity, and development needs in support of the evolving portfolio.
  • Represent Olema’s safety perspective in engagements with external stakeholders, including investigators, partners, and regulatory agencies.
  • Integrate safety considerations into program strategy and decision-making in collaboration with Clinical Development, Regulatory Affairs, Medical Affairs, and other functions.

Desired Qualifications

  • Small molecule experience is preferred.

About the Company

Olema Oncology

Clinical-stage biopharma targeting ER-positive breast cancer

Olema Oncology develops targeted therapies for women’s cancers, with a focus on ER-positive, HER2-negative breast cancer. Its lead drug, palazestrant (OP-1250), blocks and degrades the estrogen receptor (CERAN/SERD) to slow tumor growth, and a second program targets epigenetics with a KAT6 inhibitor in preclinical stages. The company is conducting a Phase 3 trial of palazestrant in combination with CDK4/6 inhibitors and has a collaboration with Novartis to test palazestrant with ribociclib and everolimus. Its goal is to bring palazestrant to market and advance the KAT6 program to clinical testing, expanding options for women with breast cancer.

Company size
51-200
Company stage
IPO
Headquarters
San Francisco, CA
Founded
2007

Recently Posted Jobs

Explore more opportunities at Olema Oncology

See more jobs